Pluristem Therapeutics (PSTI) Granted Patent In Russia For Treatment Of Inflammatory Bowel Disease Using Placenta-Derived Cells
6/19/2014 8:45:58 AM
HAIFA, Israel, June 19, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that Russia's Federal Service for Intellectual Property has granted to Pluristem Patent No. 2515156 titled, "Methods of Treating Inflammatory Colon Diseases". The patent covers methods for treating ulcerative colitis or Crohn's disease using placenta-derived cells. This patent has already been issued to Pluristem in South Africa and is currently pending in several other jurisdictions.
Help employers find you! Check out all the jobs and post your resume.
comments powered by